Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012;13(5):6129-37.
doi: 10.3390/ijms13056129. Epub 2012 May 18.

Effect of FTY720 on some physiological indexes of Non-Obese Diabetic (NOD) Mice

Xiaoqiang Chen  1 , Sudan Ye, Shikang Zhang, Jianrong Li, Hongying Zhu, Gaoli Zheng, Yin Lu, Haitong Wan
Affiliations

Effect of FTY720 on some physiological indexes of Non-Obese Diabetic (NOD) Mice

Xiaoqiang Chen et al. Int J Mol Sci. 2012.

Abstract

The studies were performed to investigate the physiological characteristics of non-obese diabetic (NOD) mice treated with FTY720. At the age of 12 weeks, each mouse was fed with FTY720 or physiological saline once a day for 10 weeks running, and their blood glucose, weight, anti-GAD antibody and organ indexes were determined. No mouse in group FTY720 (NOD mice treated with FTY720) showed diabetic symptoms. The average content of serum anti-GAD antibody in group FTY720 decreased 48.75% (P < 0.01). It was concluded that the spleen, kidney and liver of NOD mice treated with FTY720 shriveled significantly in the progression of diabetes (P < 0.01 or P < 0.05). The body weight of group FTY720 mice was slightly lower than that of the model control (MC) group and these two groups both had less body weight than the normal control (NC) group (P < 0.01). The result of tests of anti-GAD antibody suggested that FTY720 treatment could suppress the anti-GAD response.

Keywords: FTY720; non-obese diabetic (NOD) mice; physiological indexes; type 1 diabetes (T1D).

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Troncoso P., Kahan B.D. Preclinical evaluation of a new immunosuppressive agent, FTY720. Clin. Biochem. 1998;31:369–373. - PubMed
    1. Yang Z.D., Chen M., Fialkow L.B., Ellett J.D., Wu R., Brinkmann V., Nadler J.L., Lynch K.R. The immune modulator FYT720 prevents autoimmune diabetes in nonobese diabetic mice. Clin. Immunol. 2003;107:30–35. - PubMed
    1. Nikolova Z., Hof A., Rudin M., Baumlin Y., Kraus G., Hof R.P. Prevention of graft vessel disease by combined FTY720 and Cyclosporin A treatment in the DA to Lewis rat carotid artery transplantation model. Transplantation. 2000;69:2525–2530. - PubMed
    1. Hwang M.W., Matsumori A., Furukawa Y., Ono K., Okada M., Iwasaki A., Hara M., Sasayama S. FTY720, a new immunosuppressant, promotes long term graft survival and inhibits the progression of graft coronary artery diseases in a murine model of cardiac transplantation. Circulation. 1999;100:1322–1329. - PubMed
    1. Yamaski T., Inoue K., Hayashi H., Gu Y., Setoyama H., Ida J., Cui W., Kawakami Y., Kogire M., Imamura M. Effect of a new immunosuppressive agent, FYT720, on survival of islet allografts. Cell Transpl. 1998;7:403–406. - PubMed

Publication types

MeSH terms